scholarly journals Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species

2018 ◽  
Vol 73 (11) ◽  
pp. 3063-3067 ◽  
Author(s):  
Nathan P Wiederhold ◽  
Jeffrey B Locke ◽  
Paul Daruwala ◽  
Ken Bartizal
Keyword(s):  
Aspergillus Fumigatus ◽  
Cryptic Species ◽  
Vitro Activity ◽  
In Vitro Activity

scholarly journals In vitro activity of chlorogenic acid against Aspergillus fumigatus biofilm and gliotoxin production

2017 ◽  
Vol 13 (6) ◽  
pp. 2637-2644 ◽  
Author(s):  
Jin-Liang Kong ◽  
Jing Luo ◽  
Bing Li ◽  
Bi-Ying Dong ◽  
Hong Huang ◽  
...  
Keyword(s):  
Aspergillus Fumigatus ◽  
Chlorogenic Acid ◽  
Vitro Activity ◽  
In Vitro Activity

Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: evidence of enhanced in vitro activity

2003 ◽  
Vol 47 (2) ◽  
pp. 415-419 ◽  
Author(s):  
Dimitrios P. Kontoyiannis ◽  
Russell E. Lewis ◽  
Michail S. Lionakis ◽  
Nathaniel D. Albert ◽  
Gregory S. May ◽  
...  
Keyword(s):  
Aspergillus Fumigatus ◽  
Vitro Activity ◽  
In Vitro Activity

scholarly journals In Vitro Activities of Terbinafine againstAspergillus Species in Comparison with Those of Itraconazole and Amphotericin B

2001 ◽  
Vol 45 (6) ◽  
pp. 1882-1885 ◽  
Author(s):  
Caroline B. Moore ◽  
Caroline M. Walls ◽  
David W. Denning
Keyword(s):  
Aspergillus Fumigatus ◽  
Amphotericin B ◽  
Geometric Mean ◽  
Vitro Activity ◽  
Clinical Correlation ◽  
In Vitro Activity

ABSTRACT Compared with the in vitro activities of itraconazole (geometric mean MIC [GM], 0.56 μg/ml) and amphotericin B (GM, 0.66 μg/ml), the in vitro activity of terbinafine was inferior againstAspergillus fumigatus (GM, 19.03 μg/ml) (P < 0.05) and superior against A. flavus(GM, 0.10 μg/ml), A. terreus (GM, 0.16 μg/ml), andA. niger (GM, 0.19 μg/ml). Clinical correlation is required, as trailing endpoints are problematic.

In Vitro Activity of a New Antifungal Azolyl-substituted Indole Against Aspergillus fumigatus

2002 ◽  
Vol 17 (6) ◽  
pp. 425-429 ◽  
Author(s):  
Fabrice Pagniez ◽  
Marc Le Borgne ◽  
Pascal Marchand ◽  
Young Min Na ◽  
Guillaume Le Baut ◽  
...  
Keyword(s):  
Aspergillus Fumigatus ◽  
Vitro Activity ◽  
In Vitro Activity

scholarly journals Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus

1998 ◽  
Vol 42 (4) ◽  
pp. 531-533 ◽  
Author(s):  
M. Cuenca-Estrella ◽  
J. L. Rodriguez-Tudela ◽  
E. Mellado ◽  
J. V. Martinez-Suarez ◽  
A. Monzon
Keyword(s):  
Aspergillus Fumigatus ◽  
Amphotericin B ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

scholarly journals Analysis of the in vitro activity of human neutrophils against Aspergillus fumigatus in presence of antifungal and immunosuppressive agents

2017 ◽  
Vol 56 (4) ◽  
pp. 514-519 ◽  
Author(s):  
Christina Decker ◽  
Sebastian Wurster ◽  
Maria Lazariotou ◽  
Anna-Maria Hellmann ◽  
Hermann Einsele ◽  
...  
Keyword(s):  
Aspergillus Fumigatus ◽  
Immunosuppressive Agents ◽  
Vitro Activity ◽  
Human Neutrophils ◽  
In Vitro Activity

scholarly journals In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies

2021 ◽  
Vol 7 (3) ◽  
pp. 232
Author(s):  
Olga Rivero-Menendez ◽  
Juan Carlos Soto-Debran ◽  
Manuel Cuenca-Estrella ◽  
Ana Alastruey-Izquierdo
Keyword(s):  
Cryptic Species ◽  
Antifungal Susceptibility ◽  
Sensu Stricto ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Moderate Activity ◽  
In Vitro Activity ◽  
Synthesis Inhibitor ◽  
Complex Species

Ibrexafungerp is a new orally-available 1,3-β-D-glucan synthesis inhibitor in clinical development. Its in vitro activity and that of amphotericin B, voriconazole, and micafungin were evaluated against a collection of 168 clinical isolates of Aspergillus spp., including azole–susceptible and azole–resistant (Cyp51A mutants) Aspergillus fumigatus sensu stricto (s.s.) and cryptic species of Aspergillus belonging to six species complexes showing different patterns of antifungal resistance, using EUCAST and CLSI antifungal susceptibility testing reference methods. Ibrexafungerp displayed low geometric means of minimal effective concentrations (MECs) against A. fumigatus s.s. strains, both azole susceptible (0.040 mg/L by EUCAST and CLSI versus 1.231 mg/L and 0.660 mg/L for voriconazole, respectively) and azole resistant (0.092 mg/L and 0.056 mg/L, EUCAST and CLSI, while those for voriconazole were 2.144 mg/L and 2.000 mg/L). Ibrexafungerp was active against most of the cryptic species of Aspergillus tested, yielding MEC values only comparable to those of micafungin. Nevertheless, this new compound exhibited a moderate activity against A. ustus complex species, MECs ≥ 0.5 mg/L against Aspergillus insuetus and Aspergillus keveii strains, and was inactive against the Aspergillus alliaceus isolates tested (MEC90s ≥ 16 mg/L). All in all, ibrexafungerp shows encouraging in vitro results against cryptic species of Aspergillus and azole–susceptible and azole resistant strains of A. fumigatus, some of which are difficult to treat using the available therapeutic options.

Sign in / Sign up

Export Citation Format

Share Document